Information Provided By:
Fly News Breaks for September 19, 2019
ZYNE
Sep 19, 2019 | 07:27 EDT
Canaccord analyst Sumant Kulkarni noted Zynerba released positive top line data from its trial for Zygel (transdermal cannabidol) in developmental and epileptic encephalopathies. The analyst believes its safety data was misunderstood by investors especially when viewed in the context of pediatric patients. As a result, the weakness has created a buying opportunity. Kulkarni reiterated his Buy rating and $18 price target on Zynerba shares.
News For ZYNE From the Last 2 Days
There are no results for your query ZYNE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.